摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-<<(1,1-dimethylethoxy)carbonyl>amino>-21-<(1,1-dimethylethoxy)carbonyl>-11,15-dioxo-16-oxa-2,4,12,14,21,25-hexaazahexacos-2-enedioic acid, bis(1,1-dimethylethyl) ester | 185248-02-6

中文名称
——
中文别名
——
英文名称
3-<<(1,1-dimethylethoxy)carbonyl>amino>-21-<(1,1-dimethylethoxy)carbonyl>-11,15-dioxo-16-oxa-2,4,12,14,21,25-hexaazahexacos-2-enedioic acid, bis(1,1-dimethylethyl) ester
英文别名
tert-butyl N-[4-[[7-[bis[(2-methylpropan-2-yl)oxycarbonylamino]methylideneamino]heptanoylamino]methylcarbamoyloxy]butyl]-N-[3-[(2-methylpropan-2-yl)oxycarbonylamino]propyl]carbamate
3-<<(1,1-dimethylethoxy)carbonyl>amino>-21-<(1,1-dimethylethoxy)carbonyl>-11,15-dioxo-16-oxa-2,4,12,14,21,25-hexaazahexacos-2-enedioic acid, bis(1,1-dimethylethyl) ester化学式
CAS
185248-02-6
化学式
C37H69N7O11
mdl
——
分子量
787.995
InChiKey
IVZWSZRCJSODNT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.3
  • 重原子数:
    55
  • 可旋转键数:
    29
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.81
  • 拓扑面积:
    224
  • 氢给体数:
    5
  • 氢受体数:
    12

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    三氟乙酸3-<<(1,1-dimethylethoxy)carbonyl>amino>-21-<(1,1-dimethylethoxy)carbonyl>-11,15-dioxo-16-oxa-2,4,12,14,21,25-hexaazahexacos-2-enedioic acid, bis(1,1-dimethylethyl) ester二氯甲烷 为溶剂, 反应 24.0h, 以54%的产率得到7-<(aminoiminomethyl)amino>-N-<<4-<(3-aminopropyl)amino>butoxy>carbonylaminomethyl>heptanamide, tris(trifluoroacetate)
    参考文献:
    名称:
    Structure−Immunosuppressive Activity Relationships of New Analogues of 15-Deoxyspergualin. 1. Structural Modifications of the Hydroxyglycine Moiety
    摘要:
    A series of new analogues of 15-deoxyspergualin (DSG), an immunosuppressive agent currently commercialized in Japan, was synthesized and tested in a graft-versus-host disease (GVHD) model in mice. Using the general concept of bioisosteric replacement, variations of the hydroxyglycine central "C" region were made in order to determine its optimum structure in terms of in vivo immunosuppressive activity. By this way, the malonic derivative 13a was discovered as the first example of a new series of potent immunosuppressive agents encompassing a retro-amide bond linked to the hexyl-guanidino moiety. Structure-activity relationships of this series were studied by synthesizing compounds 13g-i and 13k-s. Variation of the "right-amide" of 13a led to the urea 19a and the carbamates 23 and 27a which proved to be equally active as DSG in our GVHD model. Finally 27a was found to be the most potent derivative, being slightly more active than DSG in a heart allotransplantation model in rats. Due to the absence of chiral center in its structure and to its improved chemical stability compared to DSG, 27a was selected as a candidate for clinical evaluation.
    DOI:
    10.1021/jm980431g
  • 作为产物:
    描述:
    N-(6-bromohexanoyl)glycine, ethyl ester 在 palladium on activated charcoal 、 sodium hydroxide二苯基膦叠氮化物氢气 、 sodium carbonate 、 三乙胺 作用下, 以 四氢呋喃乙二醇二甲醚乙醇甲苯 为溶剂, 25.0 ℃ 、350.0 kPa 条件下, 反应 149.75h, 生成 3-<<(1,1-dimethylethoxy)carbonyl>amino>-21-<(1,1-dimethylethoxy)carbonyl>-11,15-dioxo-16-oxa-2,4,12,14,21,25-hexaazahexacos-2-enedioic acid, bis(1,1-dimethylethyl) ester
    参考文献:
    名称:
    Structure−Immunosuppressive Activity Relationships of New Analogues of 15-Deoxyspergualin. 1. Structural Modifications of the Hydroxyglycine Moiety
    摘要:
    A series of new analogues of 15-deoxyspergualin (DSG), an immunosuppressive agent currently commercialized in Japan, was synthesized and tested in a graft-versus-host disease (GVHD) model in mice. Using the general concept of bioisosteric replacement, variations of the hydroxyglycine central "C" region were made in order to determine its optimum structure in terms of in vivo immunosuppressive activity. By this way, the malonic derivative 13a was discovered as the first example of a new series of potent immunosuppressive agents encompassing a retro-amide bond linked to the hexyl-guanidino moiety. Structure-activity relationships of this series were studied by synthesizing compounds 13g-i and 13k-s. Variation of the "right-amide" of 13a led to the urea 19a and the carbamates 23 and 27a which proved to be equally active as DSG in our GVHD model. Finally 27a was found to be the most potent derivative, being slightly more active than DSG in a heart allotransplantation model in rats. Due to the absence of chiral center in its structure and to its improved chemical stability compared to DSG, 27a was selected as a candidate for clinical evaluation.
    DOI:
    10.1021/jm980431g
点击查看最新优质反应信息

文献信息

  • US5733928A
    申请人:——
    公开号:US5733928A
    公开(公告)日:1998-03-31
  • Structure−Immunosuppressive Activity Relationships of New Analogues of 15-Deoxyspergualin. 1. Structural Modifications of the Hydroxyglycine Moiety
    作者:Luc Lebreton、Jocelyne Annat、Philippe Derrepas、Patrick Dutartre、Patrice Renaut
    DOI:10.1021/jm980431g
    日期:1999.1.1
    A series of new analogues of 15-deoxyspergualin (DSG), an immunosuppressive agent currently commercialized in Japan, was synthesized and tested in a graft-versus-host disease (GVHD) model in mice. Using the general concept of bioisosteric replacement, variations of the hydroxyglycine central "C" region were made in order to determine its optimum structure in terms of in vivo immunosuppressive activity. By this way, the malonic derivative 13a was discovered as the first example of a new series of potent immunosuppressive agents encompassing a retro-amide bond linked to the hexyl-guanidino moiety. Structure-activity relationships of this series were studied by synthesizing compounds 13g-i and 13k-s. Variation of the "right-amide" of 13a led to the urea 19a and the carbamates 23 and 27a which proved to be equally active as DSG in our GVHD model. Finally 27a was found to be the most potent derivative, being slightly more active than DSG in a heart allotransplantation model in rats. Due to the absence of chiral center in its structure and to its improved chemical stability compared to DSG, 27a was selected as a candidate for clinical evaluation.
查看更多